With U.S. Patent No. 12,187,679 now granted, Enveric Biosciences has secured more than intellectual property—it’s staked a claim on the future of neurotherapeutics. The Cambridge-based biotech firm announced this week that its latest patent covers a class of hydroxylated psilocybin derivatives that selectively target melatonin MT1 receptors, key regulators of sleep-wake cycles and circadian rhythms.
